Edition:
United Kingdom

Tocagen Inc (TOCA.OQ)

TOCA.OQ on NASDAQ Stock Exchange Global Select Market

9.15USD
6:44pm BST
Change (% chg)

$-0.23 (-2.45%)
Prev Close
$9.38
Open
$9.36
Day's High
$9.37
Day's Low
$9.02
Volume
17,430
Avg. Vol
34,390
52-wk High
$14.49
52-wk Low
$8.32

Chart for

About

Tocagen Inc. (Tocagen) is a clinical-stage, cancer-selective gene therapy company. The Company is focused on developing product candidates designed to activate a patient’s immune system against their own cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to... (more)

Overall

Beta: --
Market Cap(Mil.): $206.81
Shares Outstanding(Mil.): 19.81
Dividend: --
Yield (%): --

Financials

  TOCA.OQ Industry Sector
P/E (TTM): -- 85.36 32.76
EPS (TTM): -1.99 -- --
ROI: -- 2.21 14.61
ROE: -- 3.85 16.34

BRIEF-Tocagen Entered Amended And Restated Loan And Security Agreement For $26.5 Mln

* TOCAGEN - ENTERED AMENDED AND RESTATED LOAN AND SECURITY AGREEMENT FOR $26.5 MILLION AS TERM LOANS FUNDED ON EFFECTIVE DATE - SEC FILING Source text: (https://bit.ly/2IEQjX8) Further company coverage:

23 May 2018

BRIEF-Tocagen And ApolloBio Enter License Agreement To Develop Toca 511 & Toca FC In Greater China

* TOCAGEN AND APOLLOBIO ENTER LICENSE AGREEMENT TO DEVELOP AND COMMERCIALIZE TOCA 511 & TOCA FC IN THE GREATER CHINA REGION

19 Apr 2018

BRIEF-Tocagen Q4 Loss Per Share $0.55

* TOCAGEN REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL AND BUSINESS RESULTS

08 Mar 2018

BRIEF-Tocagen Receives EMA Orphan Medicinal Product Designation For Toca 511 & Toca FC For Glioma Treatment

* TOCAGEN RECEIVES EUROPEAN MEDICINES AGENCY ORPHAN MEDICINAL PRODUCT DESIGNATION FOR TOCA 511 & TOCA FC FOR THE TREATMENT OF GLIOMA Source text for Eikon: Further company coverage:

07 Mar 2018

Earnings vs. Estimates